Head-to-head · WeighScore
No BS RX vs Virta Health
The verdict
No BS RX takes it — 82.8/100 to 59.7/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Twenty-four prices on one public page, four dispensing pharmacies named with street addresses, and a no-intro-rate promise the arithmetic actually supports.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | No BS RX | Virta Health |
|---|---|---|
| WeighScore | 82.8/100 | 59.7/100 |
| Grade | B− | C |
| Scorecard rank | #26 | #375 |
| Semaglutide | $179/mo month-to-month (a separate low-dose program is $140) | Not disclosed |
| Tirzepatide | $249/mo month-to-month (a separate low-dose program is $140) | Not disclosed |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #26 · B−
Strengths
- Names four dispensing pharmacies with street addresses and telephone numbers — Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx
- "No Fake Intro Rate — the price on the page is the ongoing program price" is a named commitment, and the $140 in its hero really is a month-to-month rate on a real product
- Every program row prints "503A pharmacy fulfillment" and "No dose-based price changes" on the table itself
- Six programs across four terms are published with no intake and no account
- A sleep program is priced on the same page, including a diagnostic ring study at $33/mo
Where it loses points
- The same $409 twelve-week block appears under three different monthly rates — an $11 saving against one and a $128 saving against another, styled identically
- The low-dose programs stop at twelve weeks; only the standard programs carry 24- and 52-week rungs
- The Terms name four pharmacies and no operating company
- State availability is not published, and there is no FDA-approved brand lane
Graded #375 · C
Strengths
- Offers a Responsible Prescribing track with optimized GLP-1 use
- Clinically monitored medication off-ramp toward nutrition therapy
- Nutrition-first model shown to rival GLP-1 weight loss (about 13% at 1 year)
- Provided at no cost to members through employers and health plans
- Strong evidence base for diabetes reversal and metabolic health
Where it loses points
- Primarily a nutrition program; GLP-1s are a secondary track
- Distributed via employers and health plans, no direct cash-pay
- Deliberately discourages GLP-1 use for most members
- GLP-1 access depends on the specific program the plan selects
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.